The first FDA-approved nab drug delivery technology formulation is nanoparticle albumin-bound – paclitaxel. Commercially manufactured under the pharmaceutical name of Abraxane®, nab-paclitaxel is an effective chemotherapeutic used to treat advanced and spreading pancreatic cancers, metastatic breast cancers, and non-small lung cancers. The active molecule, solvent-based paclitaxel, is highly toxic and causes severe side effects for patients, which can be significantly reduced by applying HSA as a carrier for drug delivery.
Human serum albumin (HSA) is a valuable material for nanoparticle (NP) preparation due to its improved biocompatibility, biodegradability, non-toxicity, and non-immunogenicity properties. Nab-paclitaxel is formulated by encapsulating the paclitaxel molecule inside the naturally occurring human serum albumin (HSA).